Introduction
Methods
Human subjects and left ventricular samples
Characteristics | Statistic max n = 140 |
---|---|
Gender (male) | 86 (61.43%) |
Age | 71.24 ± 12.09 |
Degree of aortic stenosis | |
None to trivial | 10 (7.14%) |
Mild | 0 (0%) |
Moderate | 15 (10.71%) |
Severe | 115 (82.14%) |
Degree of aortic insufficiency | |
None to trivial | 61 (43.57%) |
Mild | 38 (27.14%) |
Moderate | 25 (17.86%) |
Severe | 16 (11.43%) |
LV EF (%) | 57.36 ± 10.97 |
AX time (min) | 81.73 ± 27.89 |
BMI (kg/m2) | 30.76 ± 7.13 |
CAD (%) | 67 (47.86%) |
HgA1c (%) | 6.08 ± 0.90 |
Day 1 CKMB (mcg/L) | 32.00 ± 24.57 |
Pre ITLN1 (FPKM) | 59.96 IQR 5.43–303.57 n = 132 |
Post ITLN1 (FPKM) | 2.46 IQR 0.84–11.00 n = 132 |
Pre ITLN1 (ng/ml) | 32.23 ± 15.22 n = 106 |
Post ITLN1 (ng/ml) | 37.46 ± 16.84 n = 106 |
RNA sequencing
Read alignment, transcript quantification, and differential gene expression analysis
Epicardial, visceral, and subcutaneous fat samples
ITLN1 ELISA
ITLN1 Immunohistochemistry
Mesothelial cell culture and qRT-PCR
Statistical analysis
Results
Plasma ITLN1 protein levels increase while left ventricular ITLN1 RNA expression decreases following myocardial ischemia in humans
Characteristic | Beta |
p-value |
---|---|---|
Pre-ischemia ITLN1 RNA | ||
Age | 1.586 | 0.81 |
BMI | −0.40 | 0.971 |
HgA1c | −1.05 | 0.99 |
Sex (male) | −18.42 | 0.91 |
CAD | 32.15 | 0.839 |
Day 1 CKMB | 1.80 | 0.582 |
ITLN1 pre-ischemia protein | −1.06 | 0.879 |
Post-ischemia ITLN1 RNA | ||
Age | 1.08 | 0.683 |
BMI | −0.43 | 0.923 |
HgA1c | −29.44 | 0.404 |
Sex (male) | −4.55 | 0.944 |
CAD | −2.97 | 0.962 |
Day 1 CKMB | −0.39 | 0.756 |
AX time | −0.50 | 0.660 |
Pre-ischemia ITLN1 protein | ||
Age | 0.30 | 0.022* |
BMI | −0.20 | 0.340 |
HgA1c | 2.18 | 0.225 |
Sex (male) | 3.37 | 0.260 |
CAD | −2.36 | 0.424 |
Day 1 CKMB | −0.01 | 0.900 |
ITLN1 pre-ischemia RNA | −0.0002 | 0.879 |
Post-ischemia ITLN1 protein | ||
Age | 0.37 | 0.011* |
BMI | −0.26 | 0.250 |
HgA1c | 1.64 | 0.410 |
Sex (male) | −1.00 | 0.765 |
CAD | −0.24 | 0.942 |
Day 1 CKMB | −0.04 | 0.524 |
AX time | −0.01 | 0.862 |
Epicardial and visceral adipose tissue have a similar gene expression profile, characterized by enrichment of genes encoding proteins involved in innate immunity
Commonly up regulated in VAT and EAT (n = 56) | Contra regulated in VAT and EAT (n = 3) | Commonly down regulated in VAT and EAT (n = 28) |
---|---|---|
ITLN1,TGM1, PROX1, IL18, C3, FRAS1, PDPN, PLAT, UPK3B, PDE1A, CGNL1, OSR1, GATA6, KCNT2, C21orf62, FBLN1, DSC3, TFF3, RELN, SULF1, CFI, FLRT3, PLLP, SLC39A8, GLT8D4, BCHE, MEIS2, PTPRD, ALDH1A2, HSD17B6, GPM6A, ART4, TIMP1, DKFZP586H2123, SYT4, BNC1, MSLN, PTGDS, LRP2, TGM2, ITGB8, PTN, ALOX15, C4A//C4B, CLDN1, RARRES1, INMT, MMRN1, UPK1B, SLPI, C7, TCF21, CKMT1A, CCL21, HP, PKHD1L1,
|
SFRP2, CD36, CHI3L2
|
NNAT, C12orf39, CXCL14, CRHBP, XG, ALDOC, ABCD2, EGFL6, ADRA2A, MFAP5, CPM, APOB, SIM1, SIX1, NOVA1, TBX15, SNX10, ENPP1, MME, OSR2, CDKN2B, DGAT2, FOSB, CCND1, TNN, TBX5, ZFP36, KLB
|
Enrichment (%) |
p-value | |
---|---|---|
Epicardial adipose tissue | ||
Classical complement pathway | 28 | <0.001 |
Lectin induced complement pathway | 25 | <0.001 |
Complement pathway | 21 | <0.001 |
Cell/molecules of local acute inflammatory response | 17 | <0.001 |
Visceral adipose tissue | ||
Classical complement pathway | 28 | <0.001 |
Complement pathway | 26 | <0.001 |
Lectin induced complement pathway | 25 | <0.001 |